Hydroxamate-based inhibitors of deacetylases B

US8349883B2 · kind B2 · utility

Assignee

• Novartis AG · CH

Inventors

• Michael David Shultz · Lexington, US
• Christine Hiu-Tung Chen · Waltham, US
• Young Shin Cho · Cambridge, US
• Lei Jiang · Shanghai, CN
• Jianmei Fan · Newton, US
• Gang Liu · Sugar Land, US
• Dyuti Majumdar · Cambridge, US
• Jianke Li · Cambridge, US

Key dates

• Filing date: Apr 8, 2011
• Grant date: Jan 8, 2013
• Expiry date: May 22, 2031

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D471/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present teachings relate to compounds of Formula I:and pharmaceutically acceptable salts, hydrates, esters, and prodrugs thereof, wherein R1, R2, R3, Y, Z, and are as defined herein.The present teachings also provide methods of preparing compounds of Formula I and methods of using compounds of Formula I in treating, inhibiting, or preventing pathologic conditions or disorders mediated wholly or in part by deacetylases.